今日热点！工业硅价格持续下跌：供需错位格局未改 下行压力犹存

工业硅价格持续下跌：供需错位格局未改 下行压力犹存

[北京讯] 6月18日，工业硅价格延续下跌态势，市场供需错位格局依然严峻，下行压力仍存。

**数据显示，**截至6月17日，华东地区5530工业硅价格为13150元/吨，较上一交易日下跌0.5%；4210工业硅价格为13600元/吨，下跌0.4%。

**业内分析人士指出，**近期工业硅价格持续下跌，主要原因在于供需格局依然宽松。一方面，国内工业硅产能持续释放，6月上旬国内工业硅产能达到422万吨/月，环比增长2.8%。另一方面，下游需求增速放缓，尤其是多晶硅、铝合金等行业需求有所回落。

**具体来看，**在原料端，近期国内硅炭价格持续下跌，支撑工业硅成本有所回落。据SMM数据，截至6月17日，国内70品硅炭价格为11000元/吨，较上一交易日下跌0.5%；60品硅炭价格为9500元/吨，下跌0.4%。

**在需求端，**近期有机硅市场表现疲软，下游需求跟进不佳。据SMM数据，截至6月17日，国内有机硅5530价格为17500元/吨，较上一交易日下跌0.3%；4210价格为18000元/吨，下跌0.2%。多晶硅方面，近期多晶硅价格小幅下跌，成交氛围一般。据卓创资讯数据，截至6月17日，国内多晶硅价格为28500元/吨，较上一交易日下跌0.2%。

**展望后市，**业内人士认为，短期内工业硅价格仍将维持弱势运行。一方面，国内工业硅产能仍处于高位，供应压力较大；另一方面，下游需求增速放缓，对工业硅价格支撑力度不足。预计下半年，随着国内多晶硅新增产能释放，工业硅价格或将进一步承压。

**此外，**业内人士还建议，相关企业应密切关注市场供需变化，积极调整生产经营策略，化解风险，推动行业健康发展。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.